Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, IN, 46202, USA.
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, IN, 46202, USA.
Nat Commun. 2019 Dec 11;10(1):5649. doi: 10.1038/s41467-019-13542-2.
Clonal hematopoiesis of indeterminate potential (CHIP) increases with age and is associated with increased risks of hematological malignancies. While TP53 mutations have been identified in CHIP, the molecular mechanisms by which mutant p53 promotes hematopoietic stem and progenitor cell (HSPC) expansion are largely unknown. Here we discover that mutant p53 confers a competitive advantage to HSPCs following transplantation and promotes HSPC expansion after radiation-induced stress. Mechanistically, mutant p53 interacts with EZH2 and enhances its association with the chromatin, thereby increasing the levels of H3K27me3 in genes regulating HSPC self-renewal and differentiation. Furthermore, genetic and pharmacological inhibition of EZH2 decreases the repopulating potential of p53 mutant HSPCs. Thus, we uncover an epigenetic mechanism by which mutant p53 drives clonal hematopoiesis. Our work will likely establish epigenetic regulator EZH2 as a novel therapeutic target for preventing CHIP progression and treating hematological malignancies with TP53 mutations.
不确定潜能的克隆性造血(CHIP)随年龄增长而增加,并与血液恶性肿瘤的风险增加相关。虽然已经在 CHIP 中鉴定出 TP53 突变,但突变型 p53 促进造血干细胞和祖细胞(HSPC)扩增的分子机制在很大程度上尚不清楚。在这里,我们发现突变型 p53 在移植后赋予 HSPC 竞争优势,并在辐射诱导的应激后促进 HSPC 扩增。在机制上,突变型 p53 与 EZH2 相互作用并增强其与染色质的结合,从而增加调节 HSPC 自我更新和分化的基因中 H3K27me3 的水平。此外,EZH2 的遗传和药理学抑制降低了 p53 突变 HSPC 的重编程潜力。因此,我们揭示了突变型 p53 驱动克隆性造血的表观遗传机制。我们的工作可能将表观遗传调节剂 EZH2 确立为预防 CHIP 进展和治疗具有 TP53 突变的血液恶性肿瘤的新的治疗靶标。